[1] European Association for the Study of the Liver. Clini-cal practice guidelines for them anagement of nonalcoh-olic fatty liver disease.J Hepatol,2016,64:1388-1402.
[2] Loria P, Lonardo A, Leonardi F, et al. Non-organ-speci-fic autoantibodies in nonalcoholic fatty liver disease:prevalence and correlates. Dig Dis Sci,2003,48:2173-2181.
[3] Adams LA, Lindor KD, Angulo P. The prevalence of autoa-tibodies and autoimmune hepatitis in patients with non-alcoholic fatty liver disease. Am J Gastroenterol,2004,99:1316-1320.
[4] Yatsuji S, Hashimoto E, Kaneda H,et al. Diagnosing aut-oimmune hepatitis in nonalcoholic fatty liver disease: is the International Autoimmune Hepatitis Group scoring system useful? J. Gastroenterol,2005,40:1130-1138.
[5] Takahashi A, Arinaga-Hino T, Ohira H,et al. Autoimmune hepatitisin Japan: trends in a nationwide survey. J Ga-stroenterol,2017,52:631-640.
[6] Watanabe S, Hashimoto E, Ikejima K,et al. Evidence-ba-sed clinical practice guidelines for nonalcoholic fattyliver disease/nonalcoholic steatohepatitis. Hepatol Re-s,2015,45:363-377.
[7] Eguchi Y, Hyogo H, Ono M,et al. Prevalence and assoc-iated metabolic factors of nonalcoholic fatty liver di-sease in the general population from 2009 to 2010 in J-apan: a multicenter large retrospective study. J Gastr-oenterol,2012,47:586-595. |
